AGM Statement

RNS Number:8092G
Healthcare Enterprise Group PLC
27 July 2006

27 July 2006



Healthcare Enterprise Group PLC



AGM Statement



At today's Annual General Meeting of Healthcare Enterprise Group PLC (Aim:
HCEG, "HCEG"), the international healthcare products group, the Chairman will
make the following statement to shareholders:



"Since the Group published its results on 31 May 2006, the main focus of our
efforts to achieve our stated aim of maximising shareholder value across the
Group and supported by our bank, has been on the Healthcare Sales and Services
(HSS) operation in Warrington and the Optiscope product range.



"As expected HSS has over the last two months returned to operating
profitability.  The Board anticipates that this business will record a small
loss for the first half of the financial year after the lower seasonal sales
during the summer.  We have also agreed another long term major supply agreement
with Ngamdee Cotton, a Thai cotton processor, which will supply a large
proportion of HSS's cotton products.



"We have had a positive response from a number of industry leaders following an
initial marketing campaign of the first Optiscope product, a 10mm laparoscope.
In view of this, we have retained the services of Burnham Securities, Inc, a New
York based investment bank with a well regarded healthcare practice, to assist
us in optimising the commercialisation of Optiscope, subject to the approval of
Optiscope shareholders.  Also, our production partner, Jenoptik Polymer Systems
GmbH, has confirmed that it will invest directly in the equipment and components
required for mass production of the initial Optiscope product.



"Trials of the Fertiligent product in Germany are on-going and results remain
positive. CE certification for the product has already been received. We have
delayed the inward investment by way of sale of minority stakes in Healthcare
Delivery Systems (the proposed holding company for Fertiligent) until the review
of the trial results has been completed.



 "The Board continues to review the strategic options for the broad portfolio of
Ebiox products following the specialist marketing and brand consultancy
evaluation of the relevant markets and opportunities."



Enquiries:



Healthcare Enterprise Group PLC                    020 7351 7500
Mark Tompkins, Group Chairman
Lyndon Gaborit, Executive Deputy Chairman



College Hill                                      020 7457 2020
Adrian Duffield / Corinna Dorward




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGMSEFSAWSMSESW